Department of Economics, East Carolina University, United States.
School of Public and Environmental Affairs, Indiana University and NBER, United States.
J Health Econ. 2019 Jan;63:64-80. doi: 10.1016/j.jhealeco.2018.11.002. Epub 2018 Nov 6.
This study examines how subsidized coverage affects prescription drug utilization among low-income non-elderly adults. Using the Affordable Care Act's Medicaid expansions as a source of variation and a national, all-payer pharmacy transactions database, we find that within the first 15 months of new health insurance availability, aggregate Medicaid-paid prescriptions increased 19 percent, amounting to nearly 9 new prescriptions a year, per new enrollee. We find no evidence of reductions in uninsured or privately-insured prescriptions, suggesting that new coverage did not simply substitute for other payment sources. The largest increases occurred for medications treating conditions such as diabetes and heart disease, suggesting greater price elasticity for chronic medications. Generics increased more than brand-name drugs; and utilization increased less in expansion states with higher Medicaid drug copayments. Overall, these findings suggest that prescription drug demand among low-income populations exhibits substantial price sensitivity, and insurance expansion can increase medication treatment for chronic conditions.
本研究考察了补贴性保险覆盖如何影响低收入非老年成年人的处方药使用情况。利用《平价医疗法案》的医疗补助扩展计划作为变化的来源,并利用全国性的、所有支付方的药房交易数据库,我们发现,在新医疗保险提供的最初 15 个月内,总体上 Medicaid 支付的处方增加了 19%,每个新参保人每年增加了近 9 个新处方。我们没有发现未参保或私人参保的处方减少的证据,这表明新的保险覆盖并没有简单地替代其他支付来源。最大的增长发生在治疗糖尿病和心脏病等疾病的药物上,这表明慢性病药物的价格弹性更大。仿制药的增长超过了品牌药;在 Medicaid 药品共付额较高的扩展州,利用率增长较少。总的来说,这些发现表明,低收入人群的处方药需求具有显著的价格敏感性,而保险扩展可以增加慢性病的药物治疗。